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Objectives To determine the long-term effects of delayed-release cysteamine bitartrate (DR-CYS) based on our
previous work that established the short-term noninferiority of DR-CYS every 12 hours compared with immediate-
release cysteamine bitartrate every 6 hours.
Study designWe conducted a prospective, controlled, open label, single-arm study of DR-CYS for 2 years in 40
patients to assess efficacy in depletion of cystine in peripheral white blood cells, to assess the dose required to
maintain white blood cell content of cystine <1 nmol ½ cystine/mg protein, to measure quality of life using the
Pediatric Quality of Life Inventory, change in estimated glomerular filtration rate, and change in height Z-score.
Results Through 24 months of study, the mean white blood cell content of cystine was always <1 nmol ½ cystine/
mg protein, and the dose of DR-CYS decreased from 43.5-40.1 mg/kg/d (P = .05), and the significant improvement
in social function, school function, and in total function scores on the Pediatric Quality of Life Inventory remained.
The estimated glomerular filtration rate was maintained and growth velocity was maintained at 24 months
compared with the baseline height Z-score.
Conclusions The use of a DR-CYS administered every 12 hours to patients with cystinosis is of great benefit to
their quality of life and to important biomarkers of disease control, when studied in a prospective, controlled fashion.
We suggest that DR-CYS should be considered for substrate depletion in patients with cystinosis. (J Pediatr
2014;165:528-33).
N
ephropathic cystinosis (OMIM 219800; 219900) is an autosomal recessive, systemic disease caused by defective cysti-
nosin transport of cystine out of the lysosome. Kidney failure is inevitable with the untreated disease, and multiple or-
gan failures ensue over time as well if the disease is untreated after kidney transplantation. Immediate release
cysteamine bitartrate1 treatment is effective but difficult to use long term.
A novel formulation of microspheronized, micro-encapsulated beads of cysteamine bitartrate was developed that allowedFrom the 1Division of Kidney Diseases, Department of
Pediatrics, Feinberg School of Medicine, Northwestern
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and 11Raptor Pharmaceutical Inc, Novato, CAextended pharmacokinetics (PK) and pharmacodynamics (PD) such that twice
daily administration was possible (delayed-release cysteamine bitartrate [DR-
CYS]). A pilot study in 9 patients with cystinosis (data not shown) confirmed
both the delayed release (Tmax = 2.78  1.56 and 1.22  0.51 hours for DR-
CYS and immediate release cysteamine bitartrate, respectively) and a longer
half-life (5.85  2.89 and 1.90  0.58 hours for DR-CYS and immediate release
cysteamine bitartrate, respectively) for DR-CYS. In addition, in data not shown, a
regression of the blood cysteamine area under the curve from 0-12 hours normal-
ized by dose in milligram/kilogram for DR-CYS vs the area under the curve from
0-6 hours normalized by dose in milligram/kilogram for immediate release cyste-
amine bitartrate suggested a linear relationship with a slope of 1.4136. Thus, to
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AE Adverse event
BMI Body mass index
DR-CYS Delayed-release cysteamine bitartrate
eGFR Estimated glomerular filtration rate
PD Pharmacodynamics
PedsQL Pediatric Quality of Life Inventory
PK Pharmacokinetics
WBC [cystine] White blood cell content of cystine
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1.4136 = 1.4148 times a single dose of immediate release
cysteamine bitartrate.
Based initially on the observed PK and PD discussed, we
demonstrated that in a randomized, controlled, cross-over
study of 3 weeks duration in 41 patients with nephropathic
cystinosis, DR-CYS (PROCYSBI, Raptor Pharmaceutical
Inc, Novato, California), was not inferior to immediate-
release cysteamine bitartrate (Castagon, Mylan Pharmaceuti-
cals, Pittsburgh, Pennsylvania), for control of white blood
cell content of cystine (WBC [cystine]) (reported as nano-
moles of ½ cystine/mg protein), a biomarker of the disease.2
However, in this short-term efficacy study of DR-CYS in
nephropathic cystinosis, the ability to evaluate the effect on
maintenance of optimal WBC (cystine), native kidney func-
tion, somatic growth, and the impact on quality of life was
not present. Therefore, we designed an open-label,
controlled, prospective study to answer these questions,
and provide herein the data for 2 years of treatment.
Methods
Patients with nephropathic cystinosis, their native kidneys,
and estimated glomerular filtration rate (eGFR) >30 mL/
min/1.73 m2 (>0.5 mL/s/1.73 m2) who completed the
short-term efficacy study noted above were eligible to enroll
in this prospective study, and 40/41 of these patients did so
after approval of the study by the ethics boards or institu-
tional review boards of the institutions and signed consent
from parents or adolescents and assent from minors accord-
ing to institutional policies. Patients were seen monthly for
the first 6 months of the study and quarterly thereafter. Clin-
ical laboratory assessments (hematology, chemistry, urinaly-
sis), physical examination (including basic neurologic and
skin assessments) and vital signs, ECG, body weight, body
mass index (BMI), body surface area, and an age-
appropriate qualify of life questionnaire (Pediatric Quality
of Life Inventory [PedsQL]) were made at each monthly
and quarterly visit. During these visits, blood samples for
PK (cysteamine) and PD (WBC [cystine]) were collected
0.5 hours after the DR-CYS dose administered at the study
visit. Concomitant medications and adverse events (AEs)
were collected from a written diary.
Upon entering this study, the initial DR-CYS dose was the
same as that used at the end of the short-term study. Subse-
quent DR-CYS dosing following each study visit was adjusted
by each investigator based on their evaluation of interval
WBC [cystine], and a clinically meaningful dosing change
for purposes of this study was defined by a minimum of
5% of the baseline dosage. This differentiated trivial
changes in either direction based on changes in patient
body mass alone.
We determined control of disease by the biomarker, WBC
[cystine], and its relationship to plasma [cysteamine], 30 mi-
nutes after DR-CYS dosing. We calculated eGFR using the
modified Schwartz formula indexed to an internationalcreatinine standard.3 We measured patient height by a stadi-
ometer calibrated to the nearest 0.1 cm, and body mass by a
digital scale calibrated to the nearest 0.1 kg. We calculated
body surface area by a standard equation. We calculated
the height Z-score for age using the Centers of Diseases Con-
trol and Prevention growth charts.4 We measured quality of
life by using the PedsQL. All data are reported for 24 months
of treatment with DR-CYS.
In general, cystine is quantitated from a human white
blood cell lysate prepared at each local study center by mixing
the clear supernatant obtained after centrifugation with
isotope-labeled cystine as an internal standard, and quanti-
tated by liquid chromatography mass spectrometry/mass
spectrometry. As reported previously, we converted the
amount of protein measured in this manner to a Lowry pro-
tein equivalent.5
In general terms, cysteamine is extracted from sodium hep-
arinized human plasma by a protein precipitation extraction
with acetonitrile. Before the extraction, isotope-labeled drug
is added as an internal standard, and Tris(2-carboxyethyl)
phosphine hydrochloride is added as a reducing agent. A su-
pernatant is transferred to a new plate, and diluted withmobile
phase. The sample is injected into a liquid chromatography
mass spectrometry/mass spectrometry system using a Waters
(hydrophilic interaction chromatography column; Waters
Corp, Milford, Massachusetts) column with an ammonium
formate/acetonitrile/water mobile phase.
Hematology, chemistry, and a urinalysis were provided by
Covance Central Laboratory Services.6 We do not report on
the specific measurements because there have been no
changes in them over time, but we use the serum creatinine
for eGFR calculations.
Statistical Analyses
Longitudinal data were analyzed using a mixed model AN-
OVA. This model allowed for a variable number of repeat
evaluations per subject and took into account the variability
specific to each subject (intrasubject variance). Linear regres-
sions were then calculated using the least-square means for
each time point. Statistical significance is P < .05. Statistical
analyses were performed with SAS Software v 9.2 (SAS Insti-
tute, Cary, North Carolina).
Results
Forty patients were enrolled (Table I; available at www.jpeds.
com). Patients were mostly children, male and female, with
an average age of almost 12 years, a height Z-score of
1.15, and with an eGFR = 63 mL/min/1.73 m2 (1.05 mL/
s/1.73 m2).
Control of WBC [cystine]
Over 24 months of study, the meanWBC [cystine] was main-
tained under optimal control (<1 nmol ½ cystine/mg pro-
tein) at all times for the study cohort (baseline:
0.43  0.15, mean  SD; median 0.31; first and third IQR529
Figure 1. A,Mean WBC (cystine) remained below 1 nmol ½
cystine/mg protein during the entire study. The solid line de-
notes the optimal upper level of WBC (cystine) to be achieved
during substrate reduction therapywith cysteamine. Therewas
no significant change in the WBC (cystine) over the 24-month
study. B, The total daily dose (mg/kg/day) of DR-CYS in the
study population over the study was reduced significantly. The
box plots below show the median (), mean (A), and the first
and third quartiles denoted by the upper and lower ends of the
box, respectively. The lower and upper whiskers denote the
minimum and maximum, respectively, and the (B) represent
the outliers. Themeandosewas reduced from43.5 to 40.1mg/
kg/d, P = .05, during the 24-month study.
Figure 2. WBC (cystine) vs plasma (cysteamine) for all study
patients who had a WBC (cystine) #1 nmol/1/2 cystine/mg
protein; 94.5% of measured plasma (cysteamine) values were
>0.1 mg/dL when the WBC (cystine) was #1 nmol ½ cystine/
mg protein.
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24 months: 0.55  0.34; median 0.53; first and third IQR
0.34 and 0.68 nmol ½ cystine/mg protein, respectively;
P = .38; Figure 1). This was achieved with a mean
reduction in DR-CYS dosing over the same time interval
from 43.5  10.8 (median, 44.4; first and third IQR 34.8
and 49.3, respectively) to 40.1  13.1 (median 39.4; first
and third IQR 33.7 and 43.3 respectively) mg/kg/
d (P = .05) (Figure 2). When the patients had a value for
plasma (cysteamine) $ 0.1 mg/L 0.5 hours after DR-CYS
dosing, 94.5% of WBC [cystine] levels were <1 (Figure 3).530Patient Growth
No patient using growth hormone during the study were
evaluated for growth change with the other members of the
study. Compared with baseline height Z-score
(1.15  0.93; median 1.22; first and third IQR 1.87
and 0.64, respectively), we found that the height Z-score
did not change over the 24-month period of study
(1.21  0.96; median 1.24; first and third IQR 1.90
and 0.70, respectively; P = .46). Similarly, the patient’s
BMI did not change significantly during the study (baseline:
18.2  3.1 vs 18.3  3.2 kg/m2, respectively; P = .27).
Evolution of eGFR
eGFR was maintained for 24 months of study (baseline:
63  25; median 58.5; first and third IQR, 43.8 and
84.5 mL/min/1.73 m2 (baseline: 1.05  0.42; median, 0.98;
first and third IQR, 0.73 and 1.40 mL/s/1.73 m2) respectively;
24-months: 57  25; median, 56.2; first and third IQR, 40.4
and 69.1 mL/min/1.73 m2 (24-months: 0.95 mL/s/1.73 m2;
median, 0.94; first and third IQR, 0.67 and 1.15 mL/s/
1.73 m2), respectively; P = .32). During this 24-month
period, 1 patient went to transplantation at 17 months, and
1 patient withdrew from the study at 21 months with a
decline in eGFR and was placed on maintenance dialysis.
Quality of Life
Upon entering this study, and using the PedsQL, we docu-
mented a significant change in the patients as they switched
from immediate-release cysteamine to DR-CYS in 3 mea-
sures: the social function (P = .049), school function
(P = .004), and in total function (P = .048). We assessed
the subsequent change from all baseline values in the PedsQL,
and demonstrated that after 2 years of DR-CYS therapy, the 3
significant changes persisted, and there were no significantLangman et al
Figure 3. A, Evolution of height (Z-score) over the 24-month
study. Therewas no significant change in height Z-socre during
the 24-month study. B, The eGFR of the study population over
time. The box plots below show themedian (), mean (A), and
the first and third quartiles denoted by the upper and lower
ends of the box, respectively. The lower and upper whiskers
denote the minimum and maximum, respectively, and the (B)
represent the outliers. The mean eGFR did not decline signifi-
cantly during the course of the 24-month study.
Table II. PedsQL percent change from baseline over the
24-month study
Functionality parameter
Physical Emotional Social School Total
Intercept (LSM) 6.62 6.62 11.23 14.27 5.99
P value .160 .136 .049 .004 .048
Slope 0.302 0.019 0.492 0.126 0.184
P value .054 .890 .201 .598 .072
LSM, least squares mean.
To summarize the analyses of percent change in PedsQL item scores from baseline, regression
analyses with a mixed model of ANOVA were performed. The intercept value (LSM) represents
the change from the value under immediate release cysteamine from the prior study2 with its
accompanying P value for that change. The slope represents the change from that new baseline
during the 24 months of the current study using DR-CYS. There was no loss of the significant
changes gained in the social, school, and total function parameters and no decline in the other 2
measured parameters (physical and emotional) during the 24-month study.
September 2014 ORIGINAL ARTICLESlosses of quality of life in the other 2 measures (physical,
emotional) (Table II).
Safety
There were no unexpected or serious safety concerns experi-
enced by subjects in the current study attributable to DR-
CYS. The incidence of AEs during this study was reduced
to 0.059 AEs per individual per month at 24 months
compared with 0.30 AEs per individual per month as
determined during the period of treatment under
immediate-release cysteamine bitartrate in our prior study.2
More specifically, all 40 (100.0%) of the subjects have expe-
rienced 1 or more treatment-emergent AEs. Gastrointestinal
disorders were the highest subject treatement emergent
adverse event incidence experienced by 35 (87.5%) subjects.
Expressed in terms of specific symptoms, emesis was experi-Quality of Life is Improved and Kidney Function Preserved in Pati
with Delayed-Release Cysteamine Bitartrateenced by 28 (70.0%) subjects, followed by headache in 14
(35.0%) subjects, upper respiratory tract symptoms in 9
(22.5%) subjects, and diarrhea in 8 (20.0%) subjects.
Discussion
Nephropathic cystinosis is a systemic disease that results in
kidney failure at the end of the first decade of life when un-
treated,7-9 or even when treatment is initiated after 5 years
of age with immediate release cysteamine therapy.10 To
date, the only studies evaluating such therapy in patients
with the disorder have been observational and retrospec-
tive.9,10 Such studies have suggested that immediate release
cysteamine improves ultimate outcomes by reducing the fre-
quency of hypothyroidism, diabetes, neuromuscular disor-
ders, or death long-term.10-12 Treatment before age 5 years
may preserve kidney function in some patients.10 Such out-
comes may be linked toWBC [cystine] itself, a marker of dis-
ease control, but such observations have not rigorously
controlled for this exposure.9,10 However, optimal control
of the disease, a WBC [cystine] <1 nmol ½ cystine/mg pro-
tein, has never been reported in a cohort of patients because
of the inherent difficulties in having patients remain adherent
to the every six hours regimen required for immediate release
therapy to achieve such control.13
In contrast, we provide 2 years of data with optimal control
of the disease under a controlled protocol and demonstrate
that with DR-CYS, there was preservation of kidney function,
stable somatic growth, and BMI. Importantly, quality of life
improved in several subscales and in total function as patients
switched to delayed release cysteamine compared with imme-
diate release cysteamine, and these changes were maintained
for the entire 24-month period. None of the other subscales
were lower at the end of the study. In addition, we found no
untoward side effects or safety concerns with DR-CYS and
an overall slight decrease in overall AEs (data not reported).
Two large series of patients have examined retrospectively the
relationship between the age of treatment initiation with imme-
diate release cysteamine therapy and subsequent kidney func-
tional outcomes in nephropathic cystinosis.10,14 When used
either before 2 years of age, and with a median WBC (cystine)ents with Nephropathic Cystinosis Treated for 2 Years 531
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representative of only 25.4% of the reported study popula-
tion),14 or when used before 5 years of age and with a mean
WBC (cystine)#2 nmol ½ cystine/mg protein (representative
of only 29.3% of the study population reported),10 there was
preservation of reduced kidney function. This attests to the
inability to maintain optimal disease control with immediate-
release cysteamine formost patients with nephropathic cystino-
sis, and that progressive chronic kidney disease is inevitable.
We studied patients at a mean age and a similar level of
reduced kidney function to those reported by Markello
et al.9 In their study, the slope of the line describing subse-
quent years of kidney function in the ‘adequate treatment’
group was downward trending, but not as steep as those un-
treated or poorly treated. In distinction, in the current study
using DR-CYS, we demonstrated that prospective, optimal
control of disease activity (WBC [cystine] < 1 nmol ½
cystine/mg protein) did not lead to a downward slope change
in eGFR during the 2 years of treatment.
What might account for the differences in outcomes of
kidney function between immediate release cysteamine and
DR-CYS? First, we targeted patients with an optimal level
of disease control, and by having a prospective, controlled
study protocol, could maintain our target values, rather
than relying on observational data alone. In fact, our mean
WBC [cystine] was always below 1 nmol ½ cystine/mg pro-
tein, and the patients reported in the retrospective study as
using immediate release cysteamine and having ‘adequate
treatment’ had amedian value of#2 nmol ½ cystine/mg pro-
tein, defining a population well above the levels we achieved.9
Second, we would suggest that the adherence was superior
with DR-CYS in our study compared with immediate-
release cysteamine in observational studies, as we were able
to maintain optimal disease control through measured
WBC [cystine] at a lower dose of DR-CYS over time in the
entire cohort. This likely is due to the ability to have the
drug taken every 12 hours compared with the need to have
every 6-hour dosing with immediate release cysteamine.
Consistent with our hypothesis that increased adherence
was an important component of outcome in our patients
treated with DR-CYS for 2 years, are the additional observa-
tions we made of preservation of statural growth, stability of
BMI, and improved measures of quality of life.
Our study provided a new insight into the management of
nephropathic cystinosis, based on the measurements of
plasma [cysteamine]. Given the observation that 94.5% of
measured WBC [cystine] values demonstrated optimal con-
trol (<1 nmol ½ cystine/mg protein) when the plasma [cyste-
amine] was >0.1 mg/L 0.5 hours after the DR-CYS dose,
patients might have only plasma [cysteamine] measured in
follow-up care. Importantly, this measure of plasma [cyste-
amine] does not reflect long-term drug adherence, but rather
that the dose administered to the patient is sufficient for
optimal disease control. Furthermore, until more data are
available, we would suggest that such means of patient
follow-up be limited to those having demonstrated optimal
control for a period of time.532Our study had limitations. We did not directly compare a
2-year treatment period between DR-CYS and immediate
release cysteamine. This was purposeful, following the obser-
vation we made of noninferiority of DR-CYS compared with
immediate release cysteamine for optimal disease control
measured by WBC (cystine).2 As has been well documented
many times, patients in clinical trials may have outcomes
based on higher adherence than in real world care. However,
given the ability to dose every 12 hours and avoid a middle of
the night dose required for immediate release cysteamine,
real world adherence may more closely mimic that which
we observed in the current study. Lastly, we studied only pre-
viously, optimally controlled patients under immediate
release cysteamine therapy, which by historical record repre-
sents a minority of patients with nephropathic cystinosis.
Current ongoing studies with DR-CYS in both treatment-
na€ıve patients and in those not optimally controlled patients
with immediate release cysteamine will answer additional
questions about the utility of DR-CYS in a broader popula-
tion of patients with cystinosis. In addition, longer-term out-
comes using DR-CYS should be done to obtain further
evidence of the important effects we observed after 2 years
of treatment.
The blood level of WBC [cystine] maintained below
1 nmol ½ cystine/mg protein for 2 years is associated with
preservation of native kidney function, stable statural
growth, stable body mass, and improved quality of life.
Although the longer-term consequences of DR-CYS use
remain unknown at present, it is highly encouraging to sug-
gest that increased adherence may result from this new ther-
apeutic agent’s every 12 hour dosing regimen, and the
improvements we documented on patient-centered quality
of life measures. n
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Table I. Baseline characteristics for enrolled patients
Baseline
40
Age (y) 11.5  3.6
Children (from age 6 to #12) 25
Adolescents (from age 12 to #21) 15
Adults (>21) 0
Male, n (%) 23 (57.5%)
Height (cm) 139.4  19.5
Height (Z-score) 1.15  0.93
Weight (kg) 37.1  15.0
BMI (kg/m2) 18.2  3.1
BSA (m2) 1.18  0.31
eGFR (mL/min/1.73 m2) 63  25 (44;58;85)
Daily immediate release cysteamine dose (mg/d) 1807  520
Total daily DR-CYS dose (average % of
previous immediate-release cysteamine dose)
83.7  7.9
WBC (cystine) (nmol ½ cystine/mg protein) 0.79  1.68
WBC (cystine) #1 nmol ½ cystine/mg
protein; n (%)
34 (85%)
BSA, body surface area.
Values presented are the mean SD (range) and the (25th percentile; median; 75th percentile)
unless otherwise noted.
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